微信小陈
微信小章
产品简介
购买须知
| 产品名称： | NCI-H1666 H-1666, H1666 |
|---|---|
| 商品货号： | TS211345 |
| Organism： | Homo sapiens, human |
| Tissue： | lung; derived from metastatic site: pleural effusion |
| Product Format： | frozen |
| Morphology： | epithelial (many rounded cells) |
| Culture Properties： | loosely adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | adenocarcinoma; bronchoalveolar carcinoma |
| Age： | 50 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | The line was established in June 1987. |
| Clinical Data： | 50 years Caucasian female The patient received prior radiation therapy. The tissue donor was a non-smoker. |
| Complete Growth Medium： | The base medium for this cell line is RPMI-1640 Medium (ATCC 30-2001).To make the complete growth medium, add the following components to the base medium: Fetal Bovine Serum (FBS; ATCC 30-2020) to a final concentration of 5%. |
| Subculturing： | Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 10% fetal bovine serum and 5% DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 11 D13S317: 15 D16S539: 13 D5S818: 10 D7S820: 8,11 THO1: 8,9.3 TPOX: 11 vWA: 16,17 |
| Name of Depositor： | AF Gazdar, JD Minna |
| Deposited As： | Homo sapiens |
| Year of Origin： | June 1987 |
| References： | NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. Sordella R, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004. PubMed: 15284455 |